US FDA Approves Moderna’s Next-Generation COVID-19 Vaccine for Older Adults

The U.S. Food and Drug Administration (FDA) has granted approval to Moderna’s latest COVID-19 vaccine, mNEXSPIKE (mRNA-1283), for adults aged 65 and older, marking a significant step in the ongoing effort to protect vulnerable populations from severe outcomes of the virus. The announcement was made by Moderna on May 31, 2025, and represents the first vaccine approval following the FDA’s recent tightening of its regulatory criteria for COVID-19 immunizations.

In addition to those 65 and older, the vaccine is also authorized for individuals aged 12 to 64 who have at least one underlying health condition that increases their risk of severe COVID-19, as defined by the Centers for Disease Control and Prevention (CDC). This shift aligns the U.S. with updated vaccine policies in other countries, such as the UK, Canada, and Australia, where updated COVID-19 vaccines are primarily targeted at older adults and those with risk factors.

Clinical Trial Data and Efficacy

The FDA’s approval is based on data from a randomized, observer-blind, active-controlled Phase 3 clinical trial (NCT05815498) involving approximately 11,400 participants aged 12 and older. The trial demonstrated that mNEXSPIKE provided a 9.3% higher relative vaccine efficacy (rVE) compared to Moderna’s original vaccine (mRNA-1273, Spikevax®) in the overall population, and a 13.5% higher rVE in adults aged 65 and older.

Regulatory Changes and Public Health Impact

This approval follows recent changes in the FDA’s vaccine authorization process, which now requires more stringent evidence for broad population use. As a result, updated COVID-19 vaccines will primarily be available to older adults and those at higher risk, rather than the general public. FDA officials have stated that there is insufficient evidence to support routine COVID-19 vaccination for healthy children and adults without risk factors, and are calling for more placebo-controlled studies in younger and healthier populations78.

Moderna CEO Stéphane Bancel emphasized the importance of the new vaccine in protecting those most at risk, noting that COVID-19 remains a serious public health threat, with over 47,000 deaths in the U.S. last year alone25.

Disclaimer:
This article is for informational purposes only and is not intended as medical advice. For personal health decisions, consult a qualified healthcare provider. Information is based on official statements and clinical trial data available as of May 31, 2025. Regulatory guidance and vaccine recommendations may change as new evidence emerges.